Seqirus
在场
是其中之一......
CSL 是一家在股票代码 CSL (AU) 下上市的公司。
CSL 在 11 个国家有直接业务。CSL 拥有 17家子公司，其中包括 CSL Behring、CSL Behring APAC 和 CSL Behring Austria。
他们在：
高管
查看带有其 15 名主要高管的组织结构图
Seqirus 搜索最多的简介
- Stephen Marlow, General Manager and Senior Vice President, Operati...
- Chris Larkins, Senior Vice President, Global Operations
- Sharon McHale, Vice President and Global Head of Policy & Governme...
高管在CSL变化
- Elaine SorgElaine Sorg 将于20249月1作为 Independent Non-Executive Director 加入公司 (新闻发布的2024八月13号).
创建提醒
跟踪 Seqirus 的高管变动
药店
CSL 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
药店 行业的其他推荐联系人
消息
Seqirus 的最新新闻稿
- New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
- CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
- CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
- CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
- CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
- CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024 25 Flu Season
- CSL Seqirus Announces US Government Award in Response to Avian Influenza
- Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
- CSL Seqirus is Fully Prepared to Implement the FDA’s Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
- CSL Seqirus to Remove BYamagata Influenza Virus Strain from Portfolio of Influenza Vaccines
- View more press releases Close
关于 Seqirus 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Stephen Marlow 
